1 / 21

A phase III study of gemcitabine ± docetaxel for metastatic soft tissue sarcoma

A phase III study of gemcitabine ± docetaxel for metastatic soft tissue sarcoma. Maki RG, Wathen JK, Patel SR, Priebat DA, Okuno S, Samuels B, Harmon DC, Fanucchi M, Hensley ML, Reinke D, Thall PF, Benjamin RS, Baker LH CTOS 2005, Boca Raton, FL. Rationale for phase III study.

tallis
Download Presentation

A phase III study of gemcitabine ± docetaxel for metastatic soft tissue sarcoma

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. A phase III study of gemcitabine ± docetaxel for metastatic soft tissue sarcoma Maki RG, Wathen JK, Patel SR, Priebat DA, Okuno S, Samuels B, Harmon DC, Fanucchi M, Hensley ML, Reinke D, Thall PF, Benjamin RS, Baker LH CTOS 2005, Boca Raton, FL

  2. Rationale for phase III study • Gemcitabine alone has at least activity in some sarcomas (LMS, osteosarcoma, angiosarcoma), most seen when gem given in a 10 mg/m2/min rate infusion • Two phase II studies show activity of gemcitabine + docetaxel in soft tissue sarcoma (STS) • Synergy in sarcoma cell lines when given in the sequence gem→doc Merimsky O et al. Cancer Chemother Pharmacol 2000; 45:177 Patel SR et al. J Clin Oncol 2001;19:3483 Svankarova L et al. Eur J Cancer 2002; 38:556 Okuno S et al. Cancer 2003; 97:1969 Hensley ME et al. JCO 2002; 20:2824 Leu KM et al. JCO 2004; 22: 1706

  3. Purpose • Execute a phase III study of gemcitabine +/- docetaxel in patients with up to 3 prior lines of therapy for metastatic disease • Is it the controlled rate infusion of gemcitabine that yields the activity in this combination? • In which subtypes is combination active? Is the combination better, or more toxic, or both? • Utilize a novel Bayesian design, dynamic randomization, to minimize the number of patients necessary to determine a statistically significant difference between arms

  4. Entry Criteria • Recurrent STS, no GIST, KS, meso • Age ≥ 10 • Measurable disease • No more than 3 prior regimens for metastatic disease • Good organ function; T Bili ≤ ULN, Cr ≤ 2 • Not pregnant • No neuropathy > G1 • No uncontrolled CNS metastases

  5. Phase III regimens ● Dynamic randomization: Bayesian model ● 120 patient enrollment target ● Restage after cycles 2, 4, 6, 8, then ~Q 3 months

  6. Definition of response • RECIST used for classic response criteria • For purposes of the dynamic randomization model, a different definition of success was defined: • Any PR or better after 2, 4, 6, 8 cycles = success • Any RECIST progression = failure • Stability recorded as SD for any of the 1st four time points • We arbitrarily decided that lowering the failure rate is 1.3 times as important as increasing the response rate • This weighs stable disease as more important in the model than frank response

  7. p (randomization to the superior arm) by patient enrollment 100 % Superior therapy 50 % 50 % Increasing number of patients Inferior therapy 100%

  8. Dose adjustments • Recover to ANC > 1K, PLT > 100K each cycle • Sliding scale dose on d8 • ANC > 1000: full dose day 8 • ANC 500-999 or PLT 50-99: 75% dose G, (Doc) • ANC < 500 or PLT < 50: Hold Rx • Febrile neutropenia, G 3-4 non heme toxicity → 25% dose reduction • May reduce dose up to twice before stopping

  9. Status as of 3 October 2005 120 patients are enrolled; 118 are assessable for use in the dynamic randomization model U Michigan 30 MDACC 27 Washington Hosp Center 17 MSKCC 16 Mayo 14 Lutheran General, Chicago 10 Emory 5 MGH/Partners 2

  10. Tumor histology

  11. Cumulative toxicity by patient, n=120

  12. Other toxicity (total events for all cycles) *Other G3 includes: lymphopenia (4), GI bleed (2), abdominal pain, diarrhea, mucositis, cough, pleural effusion, hiccups, bone pain, back spasm/pain, rash, nail changes, hypokalemia; data as of 02 Nov 2005

  13. Interim statistical model results • p < 0.01 boundary stopping rule was not crossed for either leiomyosarcoma nor non-leiomyosarcoma groups

  14. Enrollment, n=110 Prior Irradiation

  15. Randomization probability (after n=100 patients) Prior Irradiation

  16. Combined p[ n(A,Z) > n(B,Z) | data] Prior Irradiation

  17. 0.82 (5.5:1 odds) 0.86 (7:1 odds) 0.58 (~3:2 odds) 0.65 (~2:1 odds)

  18. RECIST “Best response” data(n=116 evaluable)

  19. Response by histology 19%; 39% 33%; 61%   PR PR + SD 24wk 4 Gem PR: MFH (2), DDLS, Myxoid sarcoma 13 Gem / Tax PR: LMS (6), MFH (4), Pleo lipo (2), Rhabdo (1)

  20. Conclusions • Gemcitabine in a dose controlled rate infusion has activity against metastatic soft tissue sarcomas • Gemcitabine / docetaxel is superior to higher dose single agent gemcitabine for patients with leiomyosarcoma • There is a trend toward improved response rate with the combination of therapy for patients with other types of soft tissue sarcomas • Low platelet count most common toxicity • Nearly no febrile neutropenia using (peg)-filgrastim • Fatigue, edema, myalgias occasionally dose limiting • Dynamic randomization is an effective and ethical study design to minimize the number of patients receiving the less active therapy

  21. Acknowledgements • Patients and families who participated in this study • Lilly and Sanofi-Aventis for their participation and support • Staff at SARC and the multiple centers responsible for the execution of this study

More Related